Ad-hoc | 19 February 2015 07:00

Cytos Biotechnology AG: Invitation for an Extraordinary Shareholders’ Meeting

Cytos Biotechnology AG / Key word(s): AGM/EGM

2015-02-19 / 07:00
Release of an ad hoc announcement pursuant to Art. 53 KR.
The issuer is solely responsible for the content of this announcement.

Cytos Biotechnology Ltd. invites for an Extraordinary Shareholders’ Meeting

Schlieren (Zurich), Switzerland, February 19, 2015 – Cytos Biotechnology Ltd (“Cytos” or “the Company”), announced today that an Extraordinary Shareholders’ Meeting will take place on Monday, March 16, 2015 at 10 a.m. at Cytos’ offices in Schlieren/Zurich (Switzerland).

At this meeting, shareholders will be invited to approve the share capital increase which is needed to create the shares for the conversion of the convertible bonds into equity. Further, the conditional and authorized capital shall be amended.

The formal invitation to the meeting will be sent out within the next few days and can also be downloaded on the following website:

http://www.cytos.com/uploads/2015/EGM2015.pdf

For further information, please contact:

Cytos Biotechnology Ltd
Harry Welten, MBA
Chief Financial Officer
Tel: +41 44 733 46 46
harry.welten@cytos.com

About Cytos Biotechnology Ltd

Cytos is a public biopharmaceutical company located in Schlieren (Zurich), Switzerland. The Company is listed according to the Main Standard on the SIX Swiss Exchange Ltd under the symbol CYTN.

Forward Looking Statements
This media release contains certain forward-looking statements that involve risks and uncertainties that could cause actual results to be materially different from historical results or from any future results expressed or implied by such forward-looking statements. You are urged to consider statements that include the words “will” or “expect” or the negative of those words or other similar words to be uncertain and forward-looking. Factors that may cause actual results to differ materially from any future results expressed or implied by any forward-looking statements include scientific, business, economic and financial factors, Against the background of these uncertainties, readers should not rely on forward-looking statements. The Company assumes no responsibility for updating forward-looking statements or adapting them to future events or developments.

www.cytos.com

End of ad hoc announcement

+++++
Additional features:

Document: http://n.equitystory.com/c/fncls.ssp?u=KDVMAAJNAP
Document title: Cytos_150219_EGM_Invitation

2015-02-19 News transmitted by EQS Schweiz AG. www.eqs.com – news archive: http://switzerland.eqs.com/de/News

The issuer is responsible for the contents of the release.

Language:	English
Company:	Cytos Biotechnology AG
	Wagistr. 25
	8952 Schlieren
	Switzerland
Phone:	+41 44 733 4747
Fax:	+41 44 733 4740
E-mail:	info@cytos.com
Internet:	www.cytos.com
ISIN:	CH0011025217, CH0029060735
Valor:	–
Listed:	Regulated Unofficial Market in Berlin, Munich, Stuttgart; Open Market in Frankfurt ; SIX

End of News EQS Group News-Service

324605  2015-02-19